Your browser doesn't support javascript.
loading
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano, Emanuele; Piccini, Giulia; Licastro, Danilo; Casalino, Lorenzo; Johnson, Nicole V; Paciello, Ida; Dal Monego, Simeone; Pantano, Elisa; Manganaro, Noemi; Manenti, Alessandro; Manna, Rachele; Casa, Elisa; Hyseni, Inesa; Benincasa, Linda; Montomoli, Emanuele; Amaro, Rommie E; McLellan, Jason S; Rappuoli, Rino.
Afiliación
  • Andreano E; Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy.
  • Piccini G; VisMederi S.r.l., 53100 Siena, Italy.
  • Licastro D; ARGO Open Lab Platform for Genome Sequencing, 34149 Trieste, Italy.
  • Casalino L; Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, CA 92093.
  • Johnson NV; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX 78712.
  • Paciello I; Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy.
  • Dal Monego S; ARGO Open Lab Platform for Genome Sequencing, 34149 Trieste, Italy.
  • Pantano E; Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy.
  • Manganaro N; Monoclonal Antibody Discovery Lab, Fondazione Toscana Life Sciences, 53100 Siena, Italy.
  • Manenti A; VisMederi S.r.l., 53100 Siena, Italy.
  • Manna R; VisMederi Research S.r.l., 53100 Siena, Italy.
  • Casa E; VisMederi S.r.l., 53100 Siena, Italy.
  • Hyseni I; VisMederi S.r.l., 53100 Siena, Italy.
  • Benincasa L; VisMederi Research S.r.l., 53100 Siena, Italy.
  • Montomoli E; VisMederi S.r.l., 53100 Siena, Italy.
  • Amaro RE; VisMederi Research S.r.l., 53100 Siena, Italy.
  • McLellan JS; VisMederi Research S.r.l., 53100 Siena, Italy.
  • Rappuoli R; VisMederi S.r.l., 53100 Siena, Italy.
Proc Natl Acad Sci U S A ; 118(36)2021 09 07.
Article en En | MEDLINE | ID: mdl-34417349
ABSTRACT
To investigate the evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the immune population, we coincupi bated the authentic virus with a highly neutralizing plasma from a COVID-19 convalescent patient. The plasma fully neutralized the virus for seven passages, but, after 45 d, the deletion of F140 in the spike N-terminal domain (NTD) N3 loop led to partial breakthrough. At day 73, an E484K substitution in the receptor-binding domain (RBD) occurred, followed, at day 80, by an insertion in the NTD N5 loop containing a new glycan sequon, which generated a variant completely resistant to plasma neutralization. Computational modeling predicts that the deletion and insertion in loops N3 and N5 prevent binding of neutralizing antibodies. The recent emergence in the United Kingdom, South Africa, Brazil, and Japan of natural variants with similar changes suggests that SARS-CoV-2 has the potential to escape an effective immune response and that vaccines and antibodies able to control emerging variants should be developed.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sustitución de Aminoácidos / Anticuerpos Neutralizantes / Glicoproteína de la Espiga del Coronavirus / Enzima Convertidora de Angiotensina 2 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Prognostic_studies Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Sustitución de Aminoácidos / Anticuerpos Neutralizantes / Glicoproteína de la Espiga del Coronavirus / Enzima Convertidora de Angiotensina 2 / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Prognostic_studies Idioma: En Revista: Proc Natl Acad Sci U S A Año: 2021 Tipo del documento: Article País de afiliación: Italia